ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
AI Summary: At ASCO GU, investigators showcased belzutifan‑based combinations for renal cell carcinoma, including belzutifan with lenvatinib and perioperative belzutifan plus pembrolizumab. Data presented indicate these HIF‑2α‑targeted regimens can extend disease‑free intervals in high‑risk clear‑cell RCC, prompting interest in integrating hypoxia‑axis inhibitors into multimodal kidney‑cancer care.
Related Stories
Rezatapopt shows proof-of-concept reactivating mutant p53 in patients / 4 months
Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in MIBC / 4 months
TTLC 2026 highlights advanced NSCLC symposia and emerging data / 4 months
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 3 months
HORMAD1 emerges as a potential target in triple‑negative breast cancer / 3 months
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 3 months
Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare, Pediatric Oncology, Cancer Screening, Trump Administration and look for the RSS link.
StackHealth Time Machine